{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T08:37:17Z","timestamp":1782895037623,"version":"3.54.5"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Lysosomal acid lipase deficiency is a rare, autosomal-recessive disorder caused by inactivating mutations of the lysosomal acid lipase gene and accumulation of cholesteryl esters and triglycerides in lysosomes. Treatment with recombinant lysosomal acid lipase is effective, but involves safety risks and the production of neutralizing antibodies. In the current study, we examined gene therapy with a liver-specific, self-complementary adeno-associated virus 8 (P6-13\/rscAAV8) that encodes the human lysosomal acid lipase.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Two age cohorts of C57BL\/6J mice with homozygous lysosomal acid lipase deletion were included. A young cohort (9 weeks of age; n = 8 per dose group, four males and four females) received a single intravenous administration of P6-13\/rscAAV8 at 0.6, 2, or 6 \u00d7 10\n                      <jats:sup>12<\/jats:sup>\n                      viral genomes per kg (vg\/kg). An old cohort (28 weeks of age; n = 4 per dose group, all males) received P6-13\/rscAAV8 at 1 or 6 \u00d7 10\n                      <jats:sup>12<\/jats:sup>\n                      vg\/kg. Control mice received a non-coding vector encoding green fluorescent protein.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In the young cohort, the treatment restored expression of enzyme activity, normalized lipid profiles and body weight, mitigated enlargement of the liver and spleen, and reduced steatosis, inflammation, and fibrosis in the liver. These effects were associated with rescue of autophagic flux and mitochondrial function, as well as reduction of endoplasmic reticulum stress. Notably, the observed effects were much weaker when gene therapy with the same dose was conducted in the old cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings suggest that P6-13\/rscAAV8, when delivered early enough, may mitigate or even prevent the pathology of lysosomal acid lipase deficiency.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1822727","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T07:03:42Z","timestamp":1782889422000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Liver-specific gene therapy based on self-complementary adeno-associated virus for lysosomal acid lipase deficiency"],"prefix":"10.3389","volume":"17","author":[{"given":"Ruolan","family":"Zhang","sequence":"first","affiliation":[{"name":"School of Life Science and Biopharmaceuticals, Shenyang Pharmaceutical University","place":["Shenyang, Liaoning, China"]},{"name":"Shenyang Sunshine Pharmaceuticals","place":["Shenyang, Liaoning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Lou","sequence":"additional","affiliation":[{"name":"School of Life Science and Biopharmaceuticals, Shenyang Pharmaceutical University","place":["Shenyang, Liaoning, China"]},{"name":"Shenyang Sunshine Pharmaceuticals","place":["Shenyang, Liaoning, China"]},{"name":"Shenzhen Sciprogen Bio-pharmaceuticals","place":["Shenzhen, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Jin","sequence":"additional","affiliation":[{"name":"Shenyang Sunshine Pharmaceuticals","place":["Shenyang, Liaoning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanmei","family":"Ou","sequence":"additional","affiliation":[{"name":"Shenzhen Sciprogen Bio-pharmaceuticals","place":["Shenzhen, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"He","sequence":"additional","affiliation":[{"name":"Shenzhen Sciprogen Bio-pharmaceuticals","place":["Shenzhen, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hezhi","family":"Qu","sequence":"additional","affiliation":[{"name":"Shenzhen Sciprogen Bio-pharmaceuticals","place":["Shenzhen, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqun","family":"Yang","sequence":"additional","affiliation":[{"name":"Shenzhen Sciprogen Bio-pharmaceuticals","place":["Shenzhen, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Qu","sequence":"additional","affiliation":[{"name":"Shenzhen Sciprogen Bio-pharmaceuticals","place":["Shenzhen, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/ajg.2017.486","article-title":"Benefit of treatment with sebelipase-alfa in a 63-Year-Old patient with advanced liver and atherosclerotic disease due to lysosomal acid lipase deficiency (LAL-D)","volume":"113","author":"Aigner","year":"2018","journal-title":"Am. J. Gastroenterol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"8648","DOI":"10.3390\/ijms25168648","article-title":"Evaluation of 73 enlisted patients for liver transplant with unknown etiology reveals a late-diagnosed case of lysosomal acid lipase deficiency","volume":"25","author":"Bastos","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"B3","doi-asserted-by":"publisher","first-page":"101737","DOI":"10.1016\/j.molmet.2023.101737","article-title":"Impact of (intestinal) LAL deficiency on lipid metabolism and macrophage infiltration","volume":"73","author":"Bianco","year":"2023","journal-title":"Mol. Metab."},{"key":"B4","doi-asserted-by":"publisher","first-page":"4197","DOI":"10.3390\/ijms21124197","article-title":"Recombinant adeno-associated viral vectors (rAAV)-vector elements in ocular gene therapy clinical trials and transgene expression and bioactivity assays","volume":"21","author":"Buck","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1056\/NEJMoa1501365","article-title":"A phase 3 trial of sebelipase alfa in lysosomal acid lipase deficiency","volume":"373","author":"Burton","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.jhep.2021.10.026","article-title":"Sebelipase alfa in children and adults with lysosomal acid lipase deficiency: final results of the ARISE study","volume":"76","author":"Burton","year":"2022","journal-title":"J. Hepatol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1016\/j.ymthe.2025.04.045","article-title":"Current clinical applications of AAV-mediated gene therapy","volume":"33","author":"Byrne","year":"2025","journal-title":"Mol. Ther."},{"key":"B8","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.jhep.2018.09.028","article-title":"The global prevalence and genetic spectrum of lysosomal acid lipase deficiency: a rare condition that mimics NAFLD","volume":"70","author":"Carter","year":"2019","journal-title":"J. Hepatol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.apsb.2023.10.017","article-title":"High-throughput screening of novel TFEB agonists in protecting against acetaminophen-induced liver injury in mice","volume":"14","author":"Chao","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"B10","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.omtm.2017.11.007","article-title":"Emerging issues in AAV-mediated in vivo gene therapy","volume":"8","author":"Colella","year":"2018","journal-title":"Mol. Ther. - Methods Clin. Dev."},{"key":"B11","doi-asserted-by":"publisher","first-page":"6393","DOI":"10.1038\/s41467-021-26744-4","article-title":"Hepatic expression of GAA results in enhanced enzyme bioavailability in mice and non-human primates","volume":"12","author":"Costa-Verdera","year":"2021","journal-title":"Nat. Commun."},{"key":"B12","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S0022-2275(20)31157-3","article-title":"Lysosomal acid lipase-deficient mice: depletion of white and brown fat, severe hepatosplenomegaly, and shortened life span","volume":"42","author":"Du","year":"2001","journal-title":"J. Lipid Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3389\/fcell.2015.00003","article-title":"Lysosomal acid lipase: at the crossroads of normal and atherogenic cholesterol metabolism","volume":"3","author":"Dubland","year":"2015","journal-title":"Front. Cell Dev. Biol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2832","DOI":"10.1002\/jemt.23842","article-title":"Transmission electron microscopy of the liver mitochondria of N-Nitrosodibutylamine-treated mice","volume":"84","author":"Dutta","year":"2021","journal-title":"Microsc. Res. Tech."},{"key":"B15","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.omtm.2022.12.009","article-title":"High-efficiency purification of divergent AAV serotypes using AAVX affinity chromatography","volume":"28","author":"Florea","year":"2023","journal-title":"Mol. Ther. - Methods Clin. Dev."},{"key":"B16","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.tips.2018.12.006","article-title":"Lysosomal acid lipase: from cellular lipid handler to immunometabolic target","volume":"40","author":"Gomaraschi","year":"2019","journal-title":"Trends Pharmacol. Sci."},{"key":"B17","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1002\/hep.26366","article-title":"Therapy for lysosomal acid lipase deficiency: replacing a missing link","volume":"58","author":"Grabowski","year":"2013","journal-title":"Hepatology"},{"key":"B18","doi-asserted-by":"publisher","first-page":"4932","DOI":"10.1091\/mbc.e09-07-0559","article-title":"Macrophages create an acidic extracellular hydrolytic compartment to digest aggregated lipoproteins","volume":"20","author":"Haka","year":"2009","journal-title":"Mol. Biol. Cell"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1161\/01.ATV.0000077207.49221.06","article-title":"Lysosomal enzymes are released from cultured human macrophages, hydrolyze LDL in vitro, and are present extracellularly in human atherosclerotic lesions","volume":"23","author":"Hakala","year":"2003","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1016\/j.cca.2012.03.019","article-title":"A new method for the measurement of lysosomal acid lipase in dried blood spots using the inhibitor Lalistat 2","volume":"413","author":"Hamilton","year":"2012","journal-title":"Clin. Chim. Acta"},{"key":"B21","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1002\/cac2.12464","article-title":"HMMR alleviates endoplasmic reticulum stress by promoting autophagolysosomal activity during endoplasmic reticulum stress - driven hepatocellular carcinoma progression","volume":"43","author":"He","year":"2023","journal-title":"Cancer Commun."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e14","DOI":"10.1056\/NEJMicm1610060","article-title":"Cholesteryl ester crystals in lysosomal acid lipase deficiency","volume":"376","author":"Ivashkin","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"900","DOI":"10.3390\/cimb47110900","article-title":"Long-term liver-targeted AAV8 gene therapy for mucopolysaccharidosis IVA","volume":"47","author":"Khan","year":"2025","journal-title":"Curr. Issues Mol. Biol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.omtm.2021.04.003","article-title":"Anion-exchange HPLC assay for separation and quantification of empty and full capsids in multiple adeno-associated virus serotypes","volume":"21","author":"Khatwani","year":"2021","journal-title":"Mol. Ther.-Methods Clin. Dev."},{"key":"B25","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.molmed.2023.03.001","article-title":"Recent insights into lysosomal acid lipase deficiency","volume":"29","author":"Korbelius","year":"2023","journal-title":"Trends Mol. Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.omtm.2022.08.001","article-title":"Therapeutic efficacy of rscAAVrh74.miniCMV.LIPA gene therapy in a mouse model of lysosomal acid lipase deficiency","volume":"26","author":"Lam","year":"2022","journal-title":"Mol. Ther.-Methods Clin. Dev."},{"key":"B27","doi-asserted-by":"publisher","first-page":"4272","DOI":"10.1016\/j.ymthe.2024.10.022","article-title":"Liver-directed AAV gene therapy normalizes disease symptoms and provides cross-correction in a model of lysosomal acid lipase deficiency","volume":"32","author":"Lam","year":"2024","journal-title":"Mol. Ther."},{"key":"B28","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/s43856-025-00816-8","article-title":"Rescue of lysosomal acid lipase deficiency in mice by rAAV8 liver gene transfer","volume":"5","author":"Laurent","year":"2025","journal-title":"Commun. Med. (Lond)"},{"key":"B29","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41576-019-0205-4","article-title":"Engineering adeno-associated virus vectors for gene therapy","volume":"21","author":"Li","year":"2020","journal-title":"Nat. Rev. Genet."},{"key":"B30","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1161\/ATVBAHA.119.312136","article-title":"Lysosomal acid lipase in lipid metabolism and beyond","volume":"39","author":"Li","year":"2019","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1038\/s43018-022-00389-8","article-title":"Targeting LIPA independent of its lipase activity is a therapeutic strategy in solid tumors via induction of endoplasmic reticulum stress","volume":"3","author":"Liu","year":"2022","journal-title":"Nat. Cancer"},{"key":"B32","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2-\u0394\u0394CT method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"B33","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1111\/liv.14603","article-title":"Sebelipase alfa for lysosomal acid lipase deficiency: 5-year treatment experience from a phase 2 open-label extension study","volume":"40","author":"Malinov\u00e1","year":"2020","journal-title":"Liver Int."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1038\/mt.2008.171","article-title":"Self-complementary AAV vectors: advances and applications","volume":"16","author":"McCarty","year":"2008","journal-title":"Mol. Ther."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1038\/sj.gt.3301514","article-title":"Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis","volume":"8","author":"McCarty","year":"2001","journal-title":"Gene Ther."},{"key":"B36","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1038\/sj.gt.3302134","article-title":"Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo","volume":"10","author":"McCarty","year":"2003","journal-title":"Gene Ther."},{"key":"B37","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.omtm.2020.10.001","article-title":"Characterization of AAV-specific affinity ligands: consequences for vector purification and development strategies","volume":"19","author":"Mietzsch","year":"2020","journal-title":"Mol. Ther.-Methods Clin. Dev."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1038\/mt.2011.119","article-title":"Systemic administration of AAV8-\u03b1-galactosidase a induces humoral tolerance in nonhuman primates despite low hepatic expression","volume":"19","author":"Nietupski","year":"2011","journal-title":"Mol. Ther."},{"key":"B39","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/S2468-1253(17)30052-3","article-title":"Wolman\u2019s disease and cholesteryl ester storage disorder: the phenotypic spectrum of lysosomal acid lipase deficiency","volume":"2","author":"Pericleous","year":"2017","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/nrg2899","article-title":"Synonymous but not the same: the causes and consequences of codon bias","volume":"12","author":"Plotkin","year":"2011","journal-title":"Nat. Rev. Genet."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1056\/NEJMe1509055","article-title":"Lysosomal acid lipase deficiency - a new therapy for a genetic lipid disease","volume":"373","author":"Rader","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1194\/jlr.RA120000748","article-title":"Crystal structure of human lysosomal acid lipase and its implications in cholesteryl ester storage disease","volume":"61","author":"Rajamohan","year":"2020","journal-title":"J. Lipid Res."},{"key":"B43","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.atherosclerosis.2014.04.003","article-title":"Lysosomal acid lipase deficiency - an under-recognized cause of dyslipidaemia and liver dysfunction","volume":"235","author":"Reiner","year":"2014","journal-title":"Atherosclerosis"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1007\/s40265-015-0479-6","article-title":"Sebelipase alfa: first global approval","volume":"75","author":"Shirley","year":"2015","journal-title":"Drugs"},{"key":"B45","doi-asserted-by":"publisher","first-page":"3552","DOI":"10.3390\/nu15163552","article-title":"The role of proton-coupled amino acid transporter 2 (SLC36A2) in cold-induced thermogenesis of mice","volume":"15","author":"Shu","year":"2023","journal-title":"Nutrients"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1016\/j.ymthe.2023.02.014","article-title":"Phase I study of liver depot gene therapy in late-onset pompe disease","volume":"31","author":"Smith","year":"2023","journal-title":"Mol. Ther."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1038\/mt.2016.61","article-title":"Superior in vivo transduction of human hepatocytes using engineered AAV3 capsid","volume":"24","author":"Vercauteren","year":"2016","journal-title":"Mol. Ther."},{"key":"B48","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41392-024-01780-w","article-title":"Adeno-associated virus as a delivery vector for gene therapy of human diseases","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"B49","doi-asserted-by":"publisher","first-page":"101734","DOI":"10.1016\/j.arr.2022.101734","article-title":"Vascular dementia: a microglia\u2019s perspective","volume":"81","author":"Yang","year":"2022","journal-title":"Ageing Res. Rev."},{"key":"B50","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.omtm.2020.07.002","article-title":"AAV2\/6 gene therapy in a murine model of fabry disease results in supraphysiological enzyme activity and effective substrate reduction","volume":"18","author":"Yasuda","year":"2020","journal-title":"Mol. Ther.-Methods Clin. Dev."},{"key":"B51","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/s41575-022-00729-0","article-title":"Gene therapy for liver diseases - progress and challenges","volume":"20","author":"Zabaleta","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1822727\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T07:03:43Z","timestamp":1782889423000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1822727\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":51,"alternative-id":["10.3389\/fphar.2026.1822727"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1822727","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"article-number":"1822727"}}